Wisconsin Collaborative for Quality Healthcare

View Our Reports

print this page

Ischemic Vascular Disease: Statin Use Unless Contraindicated This is a measure developed by the Wisconsin Collaborative for Healthcare Quality (WCHQ).

Your Search Results: 13 Clinics in the Monroe Clinic health system


The results below represent the care of 624 patients with coronary and other atherosclerotic vascular disease. Read More About This Measure

Reporting Period:

Sort By Rank | Sort By Name  
Btn Export
COLONY BRANDS IOWA

The number of patients or providers is too small for
purposes of reliably reporting performance
COLONY BRANDS MONROE

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC ALBANY

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC BLANCHARDVILLE

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC BRODHEAD
N=137
96.35 %
View Historical Data
MONROE CLINIC DURAND

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC FREEPORT

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC HIGHLAND WOMENS CARE

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC LENA

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC MONROE
N=487
93.22 %
View Historical Data
MONROE CLINIC NEW GLARUS

The number of patients or providers is too small for
purposes of reliably reporting performance
MONROE CLINIC URGENT CARE

The number of patients or providers is too small for
purposes of reliably reporting performance
THE MONROE CLINIC HOSPITAL

The number of patients or providers is too small for
purposes of reliably reporting performance

The American College of Cardiology (ACC) and the American Heart Association (AHA) recommends that high-intensity statin therapy should be initiated or continued as first-line therapy in women and men less than or equal to 75 years of age who have clinical atherosclerotic cardiovascular disease, unless contraindicated.

In November 2013, the ACC and AHA Task Force on Practice Guidelines released updated guidance for the treatment of blood cholesterol. The new recommendations remove treatment targets for LDL-C for the primary or secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and recommend high or moderate intensity statin therapy based on patient risk factors. Four major statin benefit groups were identified and iIndividuals with ASCVD are one of the identified groups.


Disclaimer: Measures reported by WCHQ healthcare organizations represent a specific aspect of care in relation to an evidence-based standard, but are not clinical guidelines and do not establish standards of care.